Evidence library 26 analyses
A fisetin evidence hub covering senolytic research, human trials, bioavailability, dosing, safety and supplement quality.
Complete library
Browse every published guide, review and evidence update in this topic.
Fisetin is clearly senolytic in some experimental cell systems and strongly senotherapeutic in animals, but controlled proof of systemic senescent-cell clearance in living humans is still lacking. This...
Fisetin has strong preclinical evidence as a senotherapeutic, but human findings remain early and mixed. This evidence review separates randomized trials, human biomarker studies, animal research and cell...
Human fisetin studies use multiple schedules, and neither a high-fat meal nor morning dosing has been proved superior. This guide separates published trial procedures from practical supplement use,...
There is no single established fisetin dose. Human studies have used 100 mg/day, 200–800 mg/day, 2 mg/kg intermittent dosing, ~20 mg/kg senolytic protocols and 500 mg pharmacokinetic doses....
Fisetin is a dietary flavonol found in foods such as strawberries and apples. It has antioxidant and signalling effects and shows senolytic activity in selected cell and animal...
Fisetin is a plant flavonol with senolytic activity in selected cell and animal models. Human research now spans continuous low-dose regimens, intermittent high-dose protocols and pharmacokinetic studies, but...
There is no single Mayo Clinic fisetin protocol. Human trials use one-, two- and three-day pulses, with repeat intervals ranging from one week to 28 days. This 2026...
Fisetin lowered blood pressure in a 2026 hypertensive-rat study and has additional preclinical vascular evidence, but no published human trial has yet established a blood-pressure effect. This review...
The clinical interaction profile of concentrated fisetin is uncertain. Preclinical enzyme findings cannot predict the safety of combinations with anticoagulants, cancer drugs, immunosuppressants or other prescription medicines.
